This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 Oct 2010

New migraine use for Botox could be worth $1B

The FDA finally approved Allergan wrinkle-fighter Botox as a treatment for migraines.

Allergan has done it. The FDA finally approved its wrinkle-fighter Botox as a treatment for migraines. The new indication could add $1 billion to its current annual sales of $1.3 billion, analysts say. "This is the most meaningful market expansion that the product has had since it was approved for cosmetic use," Piper Jaffray's David Amsellem tells Bloomberg.

The new indication is specifically for patients with chronic migraines; that amounts to about 3.2 million people in the U.S. "This condition can greatly affect family, work, and social life, so it is important to have a variety of effective treatment options available," the FDA's Russell Katz says in a statement.

The expanded approval comes on the heels of an off-label marketing settlement between Allergan and the feds, in which the company agreed to pay $600 million to resolve claims that it had pushed Botox for unapproved uses--including migraine. And some aren't convinced that the evidence supports broad use

Related News